Last updated 2026-06-18
Total raised
—
Stage
Pre-Funding
Founded
2020
Headcount
2
HQ
Tel Aviv-Yafo, Israel
Sector
Health Tech & Life Sciences
About
OBCTCD24 is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-delivered, CD24-based therapeutics a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need.
Q&A
- What is the primary focus of OBCTCD24?
- OBCTCD24 is a clinical-stage biopharmaceutical company focused on developing exosome-delivered, CD24-based therapeutics to treat a wide spectrum of diseases with high unmet medical need.
- When was OBCTCD24 founded?
- OBCTCD24 was founded in August 2020.
- What is the current status of OBCTCD24?
- OBCTCD24 is currently inactive and ceased to operate in December 2021.
- Where is OBCTCD24 headquartered?
- OBCTCD24 is headquartered in Tel Aviv-Yafo, Center District, Israel.
- What is OBCTCD24's primary sector?
- OBCTCD24's primary sector is Health Tech & Life Sciences.
- Who is the CEO of OBCTCD24?
- Amalia Herszkowicz is the CEO of OBCTCD24.
- What is the product stage of OBCTCD24's therapeutics?
- The product stage of OBCTCD24's therapeutics is clinical trial.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesHealthcareProviders
Business model
B2B
Tags
autoimmune-diseasespharmaceuticalshealthcare-providersdrug-developmentbiopharmaceuticalrespiratorytherapeuticsbiotechnologyinhalation
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| linkedin.com/company/70961582 |
Identifiers & details
| Founded | 2020-8 |
|---|---|
| Employees (exact) | 2 |
| Status reason | Non Active, Dec 2021 ceased to operate |